JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Daratumumab
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 214 (final count)
- Started
- Dec 15, 2022
- Main results expected
- Jan 31, 2029
- Fully finished
- Jan 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Serious Adverse Events (SAEs)
Measured over: 3 years 7 months
Number of Participants with AEs of Special Interest (AESI)
Measured over: 3 years 7 months
Number of Participants with Pregnancies or Partner Pregnancies
Measured over: 3 years 7 months
Number of Participants with Abnormal Pregnancies as SAE
Measured over: 3 years 7 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05438043 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC